ID

12812

Description

Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02010931

Link

https://clinicaltrials.gov/show/NCT02010931

Keywords

Versions (1)
  1. 12/21/15 12/21/15 -
Uploaded on

December 21, 2015

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Acute Lymphoblastic Leukemia NCT02010931

English

Eligibility Acute Lymphoblastic Leukemia NCT02010931

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with philadelphia-negative b-precursor acute lyphmoblastic leukemia in complete hematological remission defined as less than 5 percent blasts in bone marrow after at least 3 intensive chemotherapy blocks (i.e. any standard or investigational regimen according to adult protocols as long as 3 age appropriate chemotherapy blocks were given, this also includes relapse treatment
Description

philadelphia-negative b-precursor acute lyphmoblastic leukemia in complete hematological remission

Data type

boolean

Alias
UMLS CUI [1]
C1960645
UMLS CUI [2]
C0457341
detection of minimal residual disease (molecular failure or molecular relapse) at a level of greater than or equal to 10*(-4) by pcr or greater than or equal to 10*(-3) by flow cytometry at a reference lab
Description

detection of minimal residual disease

Data type

boolean

Alias
UMLS CUI [1]
C1511791
age 15 or greater at time of initial diagnosis with acute lymphoblastic leukemia. for patients aged 15-17 treatment according to adult protocols is required
Description

age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
initial diagnosis in the year 2000 or later
Description

initial diagnosis

Data type

boolean

Alias
UMLS CUI [1]
C0011900
UMLS CUI [2]
C0332168
history of acute lymphoblastic leukemia treatment (including response to first therapy, number of prior relapses) is available
Description

patient medical history

Data type

boolean

Alias
UMLS CUI [1]
C0262926
relapse status and disease follow up after timepoint of minimal residual disease detection is available
Description

relapse status and disease follow up

Data type

boolean

Alias
UMLS CUI [1]
C1277192
UMLS CUI [2]
C0589120
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with extramedullary disease at timepoint of minimal residual disease detection
Description

extramedullary disease

Data type

boolean

Alias
UMLS CUI [1]
C1868812
use of blinatumomab within 18 months of minimal residual disease detection
Description

blinatumomab

Data type

boolean

Alias
UMLS CUI [1]
C3853839
allogeneic hematopoietic stem cell transplantation prior to minimal residual disease detection at the required level
Description

allogeneic hematopoietic stem cell transplantation

Data type

boolean

Alias
UMLS CUI [1]
C2242529
Back to the top of the page

Similar models

Eligibility Acute Lymphoblastic Leukemia NCT02010931

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
philadelphia-negative b-precursor acute lyphmoblastic leukemia in complete hematological remission
Item
patients with philadelphia-negative b-precursor acute lyphmoblastic leukemia in complete hematological remission defined as less than 5 percent blasts in bone marrow after at least 3 intensive chemotherapy blocks (i.e. any standard or investigational regimen according to adult protocols as long as 3 age appropriate chemotherapy blocks were given, this also includes relapse treatment
boolean
C1960645 (UMLS CUI [1])
C0457341 (UMLS CUI [2])
detection of minimal residual disease
Item
detection of minimal residual disease (molecular failure or molecular relapse) at a level of greater than or equal to 10*(-4) by pcr or greater than or equal to 10*(-3) by flow cytometry at a reference lab
boolean
C1511791 (UMLS CUI [1])
age
Item
age 15 or greater at time of initial diagnosis with acute lymphoblastic leukemia. for patients aged 15-17 treatment according to adult protocols is required
boolean
C0001779 (UMLS CUI [1])
initial diagnosis
Item
initial diagnosis in the year 2000 or later
boolean
C0011900 (UMLS CUI [1])
C0332168 (UMLS CUI [2])
patient medical history
Item
history of acute lymphoblastic leukemia treatment (including response to first therapy, number of prior relapses) is available
boolean
C0262926 (UMLS CUI [1])
relapse status and disease follow up
Item
relapse status and disease follow up after timepoint of minimal residual disease detection is available
boolean
C1277192 (UMLS CUI [1])
C0589120 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
extramedullary disease
Item
patients with extramedullary disease at timepoint of minimal residual disease detection
boolean
C1868812 (UMLS CUI [1])
blinatumomab
Item
use of blinatumomab within 18 months of minimal residual disease detection
boolean
C3853839 (UMLS CUI [1])
allogeneic hematopoietic stem cell transplantation
Item
allogeneic hematopoietic stem cell transplantation prior to minimal residual disease detection at the required level
boolean
C2242529 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial